In certain groups of men, glucose-6-phosphate dehydrogenase (G6PD) deficiency was linked with an increased likelihood of severe COVID-19, a Veterans Affairs cohort study found. In Black men under 65, ...
Investor's Business Daily on MSN
Denali solved a major challenge in treating a rare genetic disease. Now, shares are flying.
Denali Therapeutics solved a major challenge in Hunter syndrome treatment. Now it's ready to take its technology further.
A Chiesi Farmaceutici drug for a rare enzyme deficiency is now approved by the FDA, making it the first U.S. treatment for a disorder that leads to a range of cognitive and muscle problems. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results